查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1747292

副甲狀腺疾病市場按類型、疾病類型、給藥途徑、年齡層、性別、最終用戶、分銷管道和地區分類

Parathyroid Disorders Market, By Type, By Disorder Type, By Route of Administration, By Age Group, By Gender, By End User, By Distribution Channel, By Geography
出版日期: | 出版商: Coherent Market Insights | 英文 145 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

預計 2025 年全球甲狀旁腺疾病市場規模為 111 億美元，到 2032 年將達到 139.3 億美元，2025 年至 2032 年的年複合成長率（CAGR）為 3.3%。

報告範圍 報告詳細資訊
基準年 2024 2025年的市場規模 111億美元
效能數據 從2020年到2024年 預測期 2025年至2032年
預測期：2025-2032年複合年成長率： 3.30% 2032年價值預測 139.3億美元

近年來，全球甲狀旁腺疾病市場顯著成長，這得益於副甲狀腺疾病盛行率的上升、診斷技術的進步以及新型治療方案的開發。副甲狀腺疾病包括副甲狀腺機能亢進症和甲狀旁腺功能低下症，其特徵是副甲狀腺功能異常，導致體內鈣和磷酸鹽失衡。這些疾病會嚴重影響骨骼健康、心血管功能和整體生活品質。隨著人們對副甲狀腺疾病認知的不斷提高以及先進治療方法的普及，預計全球甲狀旁腺疾病市場在預測期內將顯著成長。

市場動態：

全球副甲狀腺疾病市場受多種因素驅動，例如副甲狀腺疾病盛行率的上升，尤其是原發性副甲狀腺功能亢進症，這種疾病在停經後女性中原發性副甲狀腺機能亢進症。此外，老年人口的成長也更容易罹患副甲狀腺疾病，預計也將刺激市場成長。診斷技術的進步，例如改進的影像技術和基因檢測，使得副甲狀腺疾病的早期發現和準確診斷成為可能，進一步推動了市場成長。此外，標靶治療和微創手術等新型治療方法的開發，擴大了治療選擇，並改善了患者的預後。然而，治療費用高昂、某些地區對副甲狀腺疾病的認知度有限以及某些治療方法的潛在副作用等因素可能會抑制市場成長。儘管存在這些限制因素，但對研發活動的日益重視、行業參與者與學術機構之間的合作以及甲狀旁腺疾病領域個性化醫療方法的興起，正在為市場帶來巨大的成長機會。

本研究的主要特點

  • 本報告對全球甲狀旁腺疾病市場進行了詳細分析，並給出了預測期（2025-2032 年）的市場規模（十億美元）和年複合成長率（CAGR%），假設基準年為 2024 年。
  • 它還強調了各個領域的潛在商機，並說明了該市場的有吸引力的投資提案矩陣。
  • 它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景和主要企業採用的競爭策略的重要見解。
  • 它根據公司亮點、產品系列、關鍵亮點、業績和策略等參數列出了全球副甲狀腺疾病市場的主要企業簡介。
  • 本報告的見解將使負責人和企業經營團隊能夠就未來的產品發布、新興趨勢、市場擴張和行銷策略做出明智的決策。
  • 本研究報告針對該產業的各個相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
  • 可以透過用於分析全球甲狀旁腺疾病市場的各種策略矩陣來促進相關人員的決策。

    目錄

第1章 調查目的與前提條件

  • 研究目標
  • 先決條件
  • 簡稱

第2章 市場展望

  • 報告描述
    • 市場定義和範圍
  • 執行摘要

第3章市場動態、法規與趨勢分析

  • 市場動態
  • 驅動程式
  • 限制因素
  • 機會
  • 影響分析
  • 主要進展
  • 監管情景
  • 產品發布/核准
  • PEST分析
  • 波特分析
  • 併購場景
  • 產業趨勢

4. 2020 年至 2032 年全球甲狀旁腺疾病市場（按類型）

  • 藥物類別
  • 副甲狀腺素（PTH）類似物
  • 雙磷酸鹽
  • 鈣興奮劑
  • 維生素 D 類似物
  • 磷酸鹽粘合劑
  • 診斷方法
  • 血液檢查
  • 影像技術
  • 尿液檢查

5. 全球副甲狀腺疾病市場（依疾病類型），2020-2032 年

  • 原發性副甲狀腺機能亢進症
  • 次發性副甲狀腺機能亢進
  • 三發性副甲狀腺機能亢進症
  • 甲狀旁腺功能低下症

6. 全球副甲狀腺疾病市場（依給藥途徑），2020 年至 2032 年

  • 口服
  • 腸外

7. 全球副甲狀腺疾病市場（依年齡族群分類），2020 年至 2032 年

  • 孩子們
  • 成人
  • 老年人

8. 2020 年至 2032 年全球副甲狀腺疾病市場（依性別分類）

  • 男人
  • 女士

9. 全球副甲狀腺疾病市場（依最終用戶分類），2020 年至 2032 年

  • 醫院
  • 專科診所
  • 門診中心
  • 研究所
  • 診斷中心
  • 家庭醫療保健

第 10 章。全球甲狀旁腺疾病市場（按分銷管道分類），2020-2032 年

  • 醫院藥房
  • 零售藥局
  • 網路藥局

第 11 章。 2020-2032 年按地區分列的全球副甲狀腺疾病市場

  • 北美洲
      • 美國
      • 加拿大
  • 拉丁美洲
      • 巴西
      • 阿根廷
      • 墨西哥
      • 其他拉丁美洲
  • 歐洲
      • 德國
      • 英國
      • 西班牙
      • 法國
      • 義大利
      • 俄羅斯
      • 其他歐洲國家
  • 亞太地區
      • 中國
      • 印度
      • 日本
      • 澳洲
      • 韓國
      • ASEAN
      • 其他亞太地區
  • 中東
      • 海灣合作理事會國家
      • 以色列
      • 其他中東地區
  • 非洲
      • 南非
      • 北非
      • 中部非洲

第12章競爭格局

  • Amgen Inc.
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi SA
  • Bristol-Myers Squibb Company
  • AbbVie Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Astellas Pharma Inc.
  • Takeda Pharmaceutical Company Limited
  • Sandoz（a Novartis division）
  • Otsuka Pharmaceutical Co., Ltd.

第 13 章分析師建議

  • 機會
  • 分析師觀點
  • Coherent Opportunity Map

第14章參考文獻與調查方法

  • 參考
  • 調查方法
  • 關於出版商
簡介目錄
Product Code: CMI7966

Global Parathyroid Disorders Market is estimated to be valued at USD 11.10 Bn in 2025 and is expected to reach USD 13.93 Bn by 2032, growing at a compound annual growth rate (CAGR) of 3.3% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 11.10 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 3.30% 2032 Value Projection: USD 13.93 Bn

The global parathyroid disorders market has witnessed significant growth in recent years, driven by the increasing prevalence of parathyroid disorders, advancements in diagnostic techniques, and the development of novel treatment options. Parathyroid disorders, which include hyperparathyroidism and hypoparathyroidism, are characterized by abnormal functioning of the parathyroid glands, leading to imbalances in calcium and phosphate levels in the body. These disorders can have severe consequences on bone health, cardiovascular function, and overall quality of life. With the rising awareness about parathyroid disorders and the availability of advanced treatment modalities, the global parathyroid disorders market is expected to experience substantial growth during the forecast period.

Market Dynamics:

The global parathyroid disorders market is driven by several factors, including the increasing prevalence of parathyroid disorders, particularly primary hyperparathyroidism, which is more common in postmenopausal women. Additionally, the growing geriatric population, which is more susceptible to parathyroid disorders, is expected to fuel market growth. Advancements in diagnostic techniques, such as improved imaging modalities and genetic testing, have enabled early detection and accurate diagnosis of parathyroid disorders, further driving market growth. Moreover, the development of novel treatment options, including targeted therapies and minimally invasive surgical procedures, has expanded the treatment landscape and improved patient outcomes. However, the market growth may be restrained by factors such as the high cost of treatments, limited awareness about parathyroid disorders in certain regions, and the potential side effects associated with some treatment options. Despite these restraints, the market presents significant opportunities for growth, driven by the increasing focus on research and development activities, collaborations between industry players and academic institutions, and the emergence of personalized medicine approaches in the field of parathyroid disorders.

Key Features of the Study:

  • This report provides in-depth analysis of the global parathyroid disorders market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global parathyroid disorders market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Amgen Inc., Eli Lilly and Company, Merck & Co., Inc., Novartis AG, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Sanofi S.A., Bristol-Myers Squibb Company, AbbVie Inc., Regeneron Pharmaceuticals, Inc., Astellas Pharma Inc., Takeda Pharmaceutical Company Limited, Sandoz (a Novartis division), and Otsuka Pharmaceutical Co., Ltd.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global parathyroid disorders market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global parathyroid disorders market

Market Segmentation

  • Type Insights (Revenue, USD Bn, 2020 - 2032)
    • Drug Class
    • Parathyroid Hormone (PTH) Analogues
    • Bisphosphonates
    • Calcimimetics
    • Vitamin D Analogues
    • Phosphate Binders
    • Diagnostic Method
    • Blood Tests
    • Imaging Techniques
    • Urine Tests
  • Disorder Type Insights (Revenue, USD Bn, 2020 - 2032)
    • Primary Hyperparathyroidism
    • Secondary Hyperparathyroidism
    • Tertiary Hyperparathyroidism
    • Hypoparathyroidism
  • Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
    • Oral
    • Parenteral
  • Age Group Insights (Revenue, USD Bn, 2020 - 2032)
    • Pediatric
    • Adult
    • Geriatric
  • Gender Insights (Revenue, USD Bn, 2020 - 2032)
    • Male
    • Female
  • End User Insights (Revenue, USD Bn, 2020 - 2032)
    • Hospitals
    • Specialty Clinics
    • Outpatient Centers
    • Research Institutes
    • Diagnostic Centers
    • Home Healthcare
  • Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Regional Insights (Revenue, USD Bn, 2020 - 2032)
    • North America
    • U.S.
    • Canada
    • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
    • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
    • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
    • Africa
    • South Africa
    • North Africa
    • Central Africa
  • Key Players Insights
    • Amgen Inc.
    • Eli Lilly and Company
    • Merck & Co., Inc.
    • Novartis AG
    • Pfizer Inc.
    • GlaxoSmithKline plc
    • Teva Pharmaceutical Industries Ltd.
    • Sanofi S.A.
    • Bristol-Myers Squibb Company
    • AbbVie Inc.
    • Regeneron Pharmaceuticals, Inc.
    • Astellas Pharma Inc.
    • Takeda Pharmaceutical Company Limited
    • Sandoz (a Novartis division)
    • Otsuka Pharmaceutical Co., Ltd.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Global Parathyroid Disorders Market, By Type
    • Global Parathyroid Disorders Market, By Disorder Type
    • Global Parathyroid Disorders Market, By Route of Administration
    • Global Parathyroid Disorders Market, By Age Group
    • Global Parathyroid Disorders Market, By Gender
    • Global Parathyroid Disorders Market, By End User
    • Global Parathyroid Disorders Market, By Distribution Channel
    • Global Parathyroid Disorders Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
  • Driver
  • Restraint
  • Opportunity
  • Impact Analysis
  • Key Developments
  • Regulatory Scenario
  • Product Launches/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario
  • Industry Trends

4. Global Parathyroid Disorders Market, By Type, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Drug Class
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Parathyroid Hormone (PTH) Analogues
  • Bisphosphonates
  • Calcimimetics
  • Vitamin D Analogues
  • Phosphate Binders
  • Diagnostic Method
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Blood Tests
  • Imaging Techniques
  • Urine Tests

5. Global Parathyroid Disorders Market, By Disorder Type, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Primary Hyperparathyroidism
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Secondary Hyperparathyroidism
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Tertiary Hyperparathyroidism
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Hypoparathyroidism
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Parathyroid Disorders Market, By Route of Administration, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Parenteral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Parathyroid Disorders Market, By Age Group, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Pediatric
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Adult
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Geriatric
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Parathyroid Disorders Market, By Gender, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Male
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Female
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Global Parathyroid Disorders Market, By End User, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Hospitals
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Specialty Clinics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Outpatient Centers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Research Institutes
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Diagnostic Centers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Home Healthcare
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

10. Global Parathyroid Disorders Market, By Distribution Channel, 202-02032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

11. Global Parathyroid Disorders Market, By Region, 2020 - 2032, Value (USD Bn)

  • Introduction
    • Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
    • Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Disorder Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • U.S.
      • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Disorder Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Disorder Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Disorder Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Disorder Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • GCC Countries
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Disorder Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
      • South Africa
      • North Africa
      • Central Africa

12. Competitive Landscape

  • Amgen Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Eli Lilly and Company
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Merck & Co., Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Novartis AG
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Pfizer Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • GlaxoSmithKline plc
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Teva Pharmaceutical Industries Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Sanofi S.A.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Bristol-Myers Squibb Company
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • AbbVie Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Regeneron Pharmaceuticals, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Astellas Pharma Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Takeda Pharmaceutical Company Limited
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Sandoz (a Novartis division)
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Otsuka Pharmaceutical Co., Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies

13. Analyst Recommendations

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

14. References and Research Methodology

  • References
  • Research Methodology
  • About us